Search

#PharmaceuticalInnovation
The New York Times @nytimes.com Β· New York City πŸ‡ΊπŸ‡Έ Β· 2d

Scientists at Bristol Myers Squibb's Devens facility are utilizing artificial intelligence to monitor critical variables in the production of disease-fighting proteins, enhancing drug manufacturing efficiency by 40% and tackling shortages, while the company faces tough competition from China's rapidly advancing biotech sector and implements cost-cutting measures in light of patent expirations and the potential impact of AI on jobs in the industry. #ArtificialIntelligence #PharmaceuticalInnovation #Biotechnology #US #CN #TH

www.nytimes.com
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
In a sterile Bristol Myers Squibb lab about an hour north of Boston, scientists in scrubs and hairnets transfer living cells to a 2,000-liter stainless steel bioreactor that grows them for weeks.
The New York Times @nytimes.com Β· New York City πŸ‡ΊπŸ‡Έ Β· 2d

In a Bristol Myers Squibb lab near Boston, scientists are utilizing artificial intelligence to optimize the production of genetically engineered proteins for disease treatment by precisely monitoring key variables in the biomanufacturing process, resulting in a 40% increase in drug production and addressing challenges related to drug shortages, while the company also faces the looming impact of cost-cutting measures and potential job losses due to automation advancements. #ArtificialIntelligence #PharmaceuticalInnovation #DrugDiscovery #US #CN #TH

www.nytimes.com
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
In a sterile Bristol Myers Squibb lab about an hour north of Boston, scientists in scrubs and hairnets transfer living cells to a 2,000-liter stainless steel bioreactor that grows them for weeks.